Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The firm is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
ALBT stock price ended at $0.4 on 金曜日, after dropping 2.44%
On the latest trading day May 08, 2026, the stock price of ALBT fell by 2.44%, dropping from $0.40 to $0.40. During the session, the stock saw a volatility of 5.26%, with prices oscillating between a daily low of $0.38 and a high of $0.40. On the latest trading day, the trading volume for ALBT decreased by 47.9K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 75.7K shares were traded, with a market value of approximately $3.2M.